Taiwan Biomaterial Co., Ltd. (TPEX:6649)

Market Cap	2.07B
Revenue (ttm)	203.27M
Net Income (ttm)	56.88M
Shares Out	42.00M
EPS (ttm)	1.35
PE Ratio	36.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,810
Average Volume	108,112
Open	51.00
Previous Close	49.30
Day's Range	49.00 - 51.00
52-Week Range	29.65 - 80.40
Beta	0.81
RSI	50.58
Earnings Date	Mar 13, 2026

About Taiwan Biomaterial

Taiwan Biomaterial Co., Ltd. engages in the development and sale of implantable medical devices in Taiwan. It offers Foamagen, a foamagen dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and nickel-titanium guidewire for guiding cerebral vascular surgery; tissue repair and regeneration products for the treatment of early osteoarthritis; and CDMO. The company was founded in 1921 and is based in Zhubei, Taiwan.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1921
• Employees: 35
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6649

Financial Performance

In 2024, Taiwan Biomaterial's revenue was 96.57 million, an increase of 32.59% compared to the previous year's 72.84 million. Losses were -1.73 million, -82.90% less than in 2023.